Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

DYRK1A is a dual‐specificity protein kinase that autophosphorylates a conserved tyrosine residue in the activation loop but phosphorylates exogenous substrates only at serine or threonine residues. Tyrosine autophosphorylation of DYRKs is a one‐off event that takes place during translation and induces the activation of the kinase. Here we characterize the beta‐carboline alkaloid harmine as a potent and specific inhibitor of DYRK1A both in vitro and in cultured cells. Comparative in vitro assays of four kinases of the DYRK family showed that harmine inhibited substrate phosphorylation by DYRK1A more potently than it inhibited substrate phosphorylation by the closely related kinase DYRK1B [half maximal inhibitory concentrations (IC50) of 33 nm versus 166 nm, respectively] and by the more distant members of the family, DYRK2 and DYRK4 (1.9 μm and 80 μm, respectively). Much higher concentrations of harmine were required to suppress tyrosine autophosphorylation of the translational intermediate of DYRK1A in a bacterial in vitro translation system (IC50 = 1.9 μm). Importantly, harmine inhibited the phosphorylation of a specific substrate by DYRK1A in cultured cells with a potency similar to that observed in vitro (IC50 = 48 nm), without negative effects on the viability of the cells. Overexpression of the DYRK1A gene on chromosome 21 has been implicated in the altered neuronal development observed in Down syndrome. Here, we show that harmine interferes with neuritogenesis in cultured hippocampal neurons. In summary, our data show that harmine inhibits DYRK1A substrate phosphorylation more potently than it inhibits tyrosine autophosphorylation, and provide evidence for a role of DYRK1A in the regulation of neurite formation.

[1]  H. Katus,et al.  DYRK1A Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy* , 2009, The Journal of Biological Chemistry.

[2]  Paul Antoine Salin,et al.  DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. , 2009, Human molecular genetics.

[3]  Min-Su Jung,et al.  QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[4]  Desmond J. Smith,et al.  Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A , 2009, PloS one.

[5]  Tao Liu,et al.  Parallel RNAi screens across different cell lines identify generic and cell type-specific regulators of actin organization and cell morphology , 2009, Genome Biology.

[6]  J. Delabar,et al.  The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. , 2008, Developmental cell.

[7]  B. Lutz,et al.  The down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4 , 2008, Neuroscience.

[8]  P. Clarke,et al.  DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine , 2008, The FEBS journal.

[9]  Xavier Estivill,et al.  DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. , 2008, American journal of human genetics.

[10]  J. Wegiel,et al.  Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  J. Wegiel,et al.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome , 2008, Acta Neuropathologica.

[12]  S. Sang,et al.  Bioavailability issues in studying the health effects of plant polyphenolic compounds. , 2008, Molecular nutrition & food research.

[13]  Reinhard Ullmann,et al.  Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. , 2008, American journal of human genetics.

[14]  F. Tejedor,et al.  The spatio‐temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development , 2008, The European journal of neuroscience.

[15]  Hyun-Jeong Cho,et al.  Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease , 2008, Journal of neurochemistry.

[16]  W. Wisden,et al.  Hammerle B., Elizalde C., Tejedor FJ.(2008) The Spatio-Temporal and subcellular Expression of the Candidate Down Syndrome Gene Mnb/Dyrk1A in the Developing Mouse Brain Suggests Distinct Sequential Roles in Neuronal Development. Eur. J. Neurosci. 27:1061-1074 (F.I.: 3.673 ) , 2008 .

[17]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[18]  K. Chung,et al.  Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome , 2007, Molecular and Cellular Neuroscience.

[19]  Y. Hwang,et al.  Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro. , 2007, Biochemistry.

[20]  R. Damoiseaux,et al.  The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. , 2007, Cell metabolism.

[21]  T. Iwatsubo,et al.  Dyrk1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation* , 2006, Journal of Biological Chemistry.

[22]  Jung Tae Lee,et al.  Putative therapeutic agents for the learning and memory deficits of people with Down syndrome. , 2006, Bioorganic & medicinal chemistry letters.

[23]  M. Dierssen,et al.  DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis , 2006, TheScientificWorldJournal.

[24]  Xin Gao,et al.  NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.

[25]  T. Iwatsubo,et al.  Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. , 2006, The Journal of biological chemistry.

[26]  W. Becker,et al.  The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site , 2006, BMC Biochemistry.

[27]  I. Ferrer,et al.  Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models , 2005, Neurobiology of Disease.

[28]  G. Elston,et al.  Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/− mouse , 2005, Neurobiology of Disease.

[29]  P. Kelly,et al.  DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. , 2005, Molecular biology of the cell.

[30]  Takuya Ueda,et al.  Protein synthesis by pure translation systems. , 2005, Methods.

[31]  P. Lochhead,et al.  Activation-Loop Autophosphorylation Is Mediated by a Novel Transitional Intermediate Form of DYRKs , 2005, Cell.

[32]  E. Rubin,et al.  Transgenic Mouse In Vivo Library of Human Down Syndrome Critical Region 1: Association between DYRK1A Overexpression, Brain Development Abnormalities, and Cell Cycle Protein Alteration , 2004, Journal of neuropathology and experimental neurology.

[33]  Jian Wang,et al.  Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. , 2004, Biochemical and biophysical research communications.

[34]  Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. , 2003, The Journal of nutrition.

[35]  D. Morrison,et al.  dDYRK2: a novel dual-specificity tyrosine-phosphorylation-regulated kinase in Drosophila. , 2003, The Biochemical journal.

[36]  J. Cerón,et al.  Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation , 2003, The European journal of neuroscience.

[37]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[38]  J. Galceran,et al.  The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications. , 2003, Journal of neural transmission. Supplementum.

[39]  K. Chung,et al.  Protein Kinase Dyrk1 Activates cAMP Response Element-binding Protein during Neuronal Differentiation in Hippocampal Progenitor Cells* , 2001, The Journal of Biological Chemistry.

[40]  T. Blundell,et al.  Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. , 2001, The Biochemical journal.

[41]  R. Poland,et al.  Pharmacokinetics of Hoasca alkaloids in healthy humans. , 1999, Journal of ethnopharmacology.

[42]  X. Estivill,et al.  Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases. , 1999, Biochemical and biophysical research communications.

[43]  H. Joost,et al.  Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases* , 1998, The Journal of Biological Chemistry.

[44]  R. Ramsay,et al.  Inhibition of Monoamine Oxidase A by β-Carboline Derivatives , 1997 .

[45]  R. Ramsay,et al.  Inhibition of monoamine oxidase A by beta-carboline derivatives. , 1997, Archives of biochemistry and biophysics.

[46]  M Heisenberg,et al.  minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila , 1995, Neuron.

[47]  Banisteria Caapi, ein neues Rauschgift und Heilmittel. Von Prof. Dr. Louis Lewin. Mit 2 Karten. Berlin 1929. Verlag von Georg Stilke. 18 Seiten , 2022 .